Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The non-functional ACE2 isoform, but not the SARS-CoV-2 receptor, is induced as an interferon-stimulated gene, in SARS-CoV-2 infected adults

Giuseppe Oliveto a,*, Carolina Scagnolari a, Federica Frasca a, Leonardo Sorrentino a, Luigi Matera b, Raffaella Nenna b, Agnese Viscido a, Mirko Scordio a, Laura Petrarca b, Anna Maria Zicari b, Elio Gentilini c, Gabriella D’Ettorre c, Giancarlo Ceccarelli c, Fabio Midulla b, Guido Antonelli a, Alessandra Pierangeli a

a Virology Laboratory, Department of Molecular Medicine, “Sapienza” University, Rome, Italy
b Department of Maternal, Infantile and Urological Sciences, “Sapienza” University, Rome, Italy
c Department of Public Health and Infectious Diseases, “Sapienza” University, Rome, Italy

1. Introduction

Infection with SARS-CoV-2 starts with the binding to its main receptor, the angiotensin-converting enzyme 2 (ACE2) in respiratory mucosal cells [1]. ACE2 relative rate of expression in specific cell types may be a determinant of the effectiveness of SARS-CoV-2 spread in the respiratory tract [2-3]; conversely, ACE2 exerts protective functions from acute lung injury and plays a role in COVID-19 outcome [4]. ACE2 expression has been proposed to be enhanced by the mucosal interferon (IFN) response, raising the concern that this may enhance efficiency of SARS-CoV-2 infection [5]. Subsequently, the existence of a short, truncated ACE2 isoform also named deltaACE2 (dACE2) was demonstrated [6-8]. The truncated protein, not able to serve as SARS-CoV-2 entry receptor, is unstable and of unknown functions [6-8]. This truncated isoform, but not the full-length ACE2 (f-ACE2), was shown to be induced by IFNs and viruses in several, but not all, cell types [6-10]. Other studies found that IFNs activated the f-ACE2 transcript also, but to a lesser extent than dACE2, in primary airway cells [11,12]. Here, we measured the differential expression of ACE2 isoforms in nasopharyngeal cells, obtaining samples from SARS-CoV-2 infected children and adults, including hospitalized patients that were not previously tested for dACE2 expression and including control individuals, in relation to the activation of IFN-stimulated genes (ISG).

Subjects (children and adults reporting contacts with a SARS-CoV-2 positive case, asymptomatic medicine students and health workers attending periodic screening, adults presenting with respiratory symptoms) were enrolled during February-May 2021 when attending emergency departments (ED) of Sapienza University Hospital, to perform the SARS-CoV-2 molecular tests. Deidentified data were collected after an informed consent was signed; the study was approved by the Hospital Review board and the Ethics Committee (Rif. 5836, Prot. 0690/2021). Nasopharyngeal swabs (NPS) were taken for SARS-CoV-2 detection using RealStar® SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics, Germany), targeting E and S viral genes. Within 3 h from SARS-CoV-2 molecular testing, total RNA was extracted from NPS residual cells. Levels of f-ACE2 and dACE2 transcripts using isoform-specific primers and probes validated for specificity in previous studies [6,9], and of the well-known markers of IFNs’ activation, ISG15 and ISG56, were measured by quantitative Reverse Transcription-Real time PCR assays, in co-amplification with the beta-glucuronidase (GUS) invariant gene [9]. The mRNA copy number of target genes was calculated using the threshold cycle (Ct) relative quantification to the GUS Ct of the same
Relative expression values of f-ACE2, dACE2, ISG15, ISG56 and the f-ACE2/dACE2 ratio were log transformed and compared using multi-variable regression analysis, controlling for age and sex. For categorical variables (including the f-ACE2/dACE2 ratio stratified as < 0 or ≥ 0), Pearlson’s chi-square test was used to test significance. Pearlson’s coefficients were calculated controlling for the confounding variables age and sex, to assess partial correlations between f-ACE2, dACE2 and their ratio, with ISG15 and age in years. Analysis was performed with SPSS v.27 (IBM).

Residual NPS cells from 111 adults and 53 children were tested for the expression of ACE2 isoforms. In 38/53 children’s NPS (71.7 %), dACE2 expression was not detectable and, in several others, very low levels of either dACE2 or f-ACE2 were measured so that we could not include children’s samples in the study. This finding is not surprising given that several studies reported lower levels of ACE2 expression in children and related this to the lower susceptibility to severe SARS-CoV-2 infection compared with adults (reviewed in ref 13). In 20 adults’ NPS cells, most of which SARS-CoV-2 negative with low cell numbers (as estimated by their high GUS Ct values), dACE2 and f-ACE2 had Ct values > 40; these samples were not further analyzed. Results from 91 cases are reported in Table 1, stratified in three study groups: SARS-CoV-2 negative (n = 41), SARS-CoV-2 positive (n = 22), SARS-CoV-2 hospitalized (n = 28). No significant difference was found when comparing expression levels of the ACE2 isoforms by sex (f-ACE2 mean ± standard deviation (SD): male = -2.5 ± 1.22 vs female = -3.09 ± 1.42, p = 0.060; f-ACE2 mean ± SD: male = -2.4 ± 0.80 vs female = -2.38 ± 0.61, p = 0.994). f-ACE2, but not dACE2, showed a moderate positive correlation with age (Pearson’s coefficient = 0.270, p = 0.010).

Expression levels were then compared among three groups adjusting for age and sex (Table 1 and supplementary data); f-ACE2 and dACE2 levels were different among groups with a tendency to be higher in hospitalized patients (Table 1, Fig. 1A and B). Interestingly the f-ACE2/dACE2 ratio was significantly lower and more frequently < 0 (log dACE2 greater than log f-ACE2) in the SARS-CoV-2 positive-subjects, either hospitalized or not (Table 1, Fig. 1C).

Furthermore, a partial Pearlson’s correlation analysis indicated a moderate positive correlation exists between ISG15 and dACE2 (r = 0.353, p = 0.001; Fig. 1D) but not f-ACE2 (r = 0.157, p = 0.140). Moreover, ISG15 transcripts were significantly higher in the NPS in which the f-ACE2/dACE2 ratio was < 0, than in those with a ratio ≥ 0 [mean ± SD: 0.53 ± 0.34 vs 0.28 ± 0.35; p = 0.001].

Overall, this study detected higher levels of dACE2 expression in SARS-CoV-2 infected adults, in particular in the hospitalized patients, with respect to uninfected controls and confirmed, in the upper respiratory mucosal cells, the relationship between dACE2 and IFN-stimulated genes previously demonstrated in cell lines and tissues [6-10]. Activation of dACE2 was substantial but relatively lower compared to ISG15 and ISG56, in accordance with previous studies [6-10].

We found little difference in f-ACE2 expression between uninfected and SARS-CoV-2 infected subjects either hospitalized or not; hence, f-ACE2 seems not to be activated by the IFN system in response to a SARS-CoV-2 infection [6-8]. An alternative explanation is that a weak f-ACE2 activation by IFNs may occur, as reported [11,12], but is counter-balanced by SARS-CoV-2 downregulation of its own receptor, in analogy to SARS-CoV-1 and NL63-CoV [4,14]. In any case, given that f-ACE2 activation following SARS-CoV-2 infections was not relevant, the early concerns that IFNs might enhance the efficiency of SARS-CoV-2 infection by up-regulating viral receptor expression [5], are not supported by these findings. Nonetheless, f-ACE2 expression, beside a possible regulation by IFNs, is also determined by cell-specific promoters along the airways, and affected by host factors such as age and sex, and underlying disease [13,15]. We also found not-detectable or very low expression of both ACE2 isoforms in children, consistent with the positive correlation we observed between f-ACE2 and age in adults, but the number of samples was not sufficient to draw firm conclusions.

We also examined the f-ACE2/dACE2 ratio that is a determinant that could explain the different efficiencies of SARS-CoV-2 infection in different tissues [7]; in most SARS-CoV-2 positive cases, the ratio between the isoforms’ log values was < 0, because of the higher dACE2 activation with respect to f-ACE2. In partial disagreement, Blume et al. reported that in airway primary cells, dACE2 is upregulated in response to rhinovirus, but not to SARS-CoV-2 infection [8]; this was attributed to the lack of IFN production and downstream signaling due to the ability of SARS-CoV-2 to inhibit IFN activation. Nevertheless, an IFN-mediated response in the nasopharyngeal mucosa is activated following SARS-CoV-2 infection and can be effective in preventing severe disease [15]. Indeed, in our SARS-CoV-2 infected subjects, we could measure elevated levels of activation of two ISGs that are considered markers of mucosal IFN response. Thus, we retain that activation of dACE2 transcription could be one of the antiviral weapons of the mucosal IFN response to SARS-CoV-2.

In conclusion, we showed in NPS cells, a detectable, specific activation of dACE2 transcription that might be considered as part of the complex regulatory mechanisms driving ACE2 expression. Further studies examining differential regulation of ACE2 isoforms in larger groups are needed to clarify the interplay between SARS-CoV-2, its receptor and IFNs, produced following natural infections or administered as a therapy.

Table 1

| Study subjects       | SARS-CoV-2 negative n = 41 | SARS-CoV-2 positive n = 22 | SARS-CoV-2 hospitalized n = 28 | p-value |
|----------------------|---------------------------|---------------------------|-------------------------------|---------|
| Female/ Male         | 29/12                     | 14/8                      | 6/22                          | < 0.001 |
| Age (years)          | 39.6 ± 14.7               | 28.3 ± 5.9                | 57.2 ± 16.9                   | < 0.001 |
| Gene expression      |                           |                           |                               |         |
| Log-f-ACE2           | -2.32 (-2.52; -1.10)      | -2.77 (-3.07; -2.39)      | -2.42 (-2.48; -1.99)          | 0.02    |
| Log-dACE2            | -3.45 (-3.81; -2.86)      | -2.82 (-3.43; -2.21)      | -2.04 (-2.29; -1.79)          | 0.04    |
| Log-f-ACE2/dACE2     | 0.99 (0.60;0.138)         | 0.03 (-0.44;0.50)         | -0.20 (-0.31;0.09)            | 0.006   |
| Log-ISG15            | 0.24 (0.14;0.35)          | 0.56 (0.41;0.71)          | 0.53 (0.39;0.66)              | 0.02    |
| Log-ISG56            | -0.38 (-0.54; -0.22)      | -0.08 (0.20;0.04)         | NB (0.02)                     | 0.02    |
| Log-f-ACE2/dACE2 < 0 | 10 (24.4 %)               | 14 (63.6 %)               | 22 (78.6 %)                   | < 0.001 |

a Age is expressed as mean ± standard deviation.

b Expression levels of full-length ACE2 (f-ACE2), truncated ACE2 (dACE2), the ratio between expression levels of f-ACE2/dACE2, and of the Interferon stimulated gene (ISG) ISG15, are reported as mean (95 %CI) after log transformation of the values; p-values are reported after controlling for age and gender using regression analysis, as reported in the supplementary data.

c ISG56 is reported as mean (95 %CI) after log transformation of the values; p-value is calculated using Student’s t-test.

d Not done.

Number of samples (% to total in the group) in which the ratio between the expression levels of f-ACE2/dACE2 was < 0; p-value is calculated using Pearson’s chi-square.

CRediT authorship contribution statement

Giuseppe Oliveto: Investigation. Carolina Scagnolari:
Conceptualization, Writing – review & editing. Federica Frasca: Investigation. Leonardo Sorrentino: Investigation. Luigi Matera: Data curation. Raffaella Nenna: Data curation. Agnese Viscido: Data curation. Mirko Scordio: Data curation. Laura Petrarca: Data curation. Anna Maria Zicari: Data curation. Elio Gentilini: Data curation. Gabriella D’Ettorre: Data curation. Giancarlo Ceccarelli: Investigation. Fabio Midulla: Supervision. Guido Antonelli: Conceptualization, Formal analysis. Alessandra Pierangeli: Conceptualization, Writing – original draft.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

Acknowledgements

Funding: This work was supported by a grant from the Italian Ministry of Health: Progetto di Ricerca Finalizzata COVID-2020-12371817 to Guido Antonelli; a grant from Sapienza University (ATENEO H2020, PH120172B4BA8CAF) to Guido Antonelli.

We would like to thank members of the Diagnostic Department, the postgraduate medicine students, nurses, and physicians of the Infectious Disease Clinics, Umberto I Hospital.

Data availability

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sapienza University Hospital (Rif. 5836, Prot. 0690/2021).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/...
References

[1] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M.A. Müller, C. Drosten, S. Pöhlmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2) (2020) 271–280.e8.

[2] W. Sungnak, N.I. Huang, C. Brécavin, M. Berg, R. Queen, M. Litvinukova, C. Talavera-López, H. Maatz, D. Reichart, P. Sampaziotis, B.K. Worlock, M. Yoshida, J.L. Barnes, SARS-CoV-2 entry factors are heavily expressed in nasal epithelial cells together with innate immune genes, Nat Med 26 (5) (2020) 681–687.

[3] B.G.G. Pinto, A.E.R. Oliveira, Y. Singh, L. Jimenez, A.N.A. Gonçalves, R.L.T. Ogava, R. Creighton, J.P. Schatzmann Peron, H.I. Nakaya, ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19, J Infect Dis 222 (4) (2020) 556–563.

[4] N. Zamorano Cuervo, N. Grandvaux, ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities, Elife. 9 (9) (2020), e61390, https://doi.org/10.7554/elife.61390.

[5] C.G.K. Ziegler, S.J. Allison, S.K. Nyquist, I.M. Mbano, V.N. Miao, C.N. Tzouanas, Y. Cao, A.S. Yousif, J. Bals, B.M. Hauser, J. Feldman, C. Muus, M.H. Wadsworth, S. W. Kazer, T.K. Hughes, B. Doran, G.J. Gatter, M. Vukovic, P. Taliaferro, B.E. Mead, Z. Guo, J.P. Wang, D. Gras, M. Plassant, M. Ansari, I. Angelidis, H. Adler, J.M. Sucre, C.J. Taylor, B. Lin, A. Waghray, V. Minislaf, D.F. Dwyer, K.M. Buchheit, J. A. Boyce, N.A. Barrett, T.M. Laidlaw, S.L. Carroll, I. Coloma, V. Tkatchev, C. Peterson, A. Yu, H.B. Zheng, H.P. Gideon, C.G. Winchell, P.L. Lin, C.D. Bingle, S. B. Snapper, J.A. Kropski, F.J. Theis, H.B. Schiller, L. Barby, A. Leslie, H.-P. Klein, J.L. Flynn, S.M. Fortune, B. Berger, R.W. Finberg, L.S. Kean, M. Garber, A.G. Schmidt, D. Lingwood, A.K. Shalek, J. Ordovas-Montanes, N. Banovich, P. Barby, A. Brahma, T. Desai, T.E. Duong, O. Eickelberg, C. Falk, M. Farzan, I. Glass, M. Hainfita, P. Horvath, D. Hung, N. Kaminiski, M. Kranzov, J. A. Kropski, M. Kuboosmand, R. Lisyatsi, H. Lee, S. Leroy, S. Linarson, J. Landenberg, K. Meyer, A. Mikhailin, N. Nawijn, M.Z. Nikolic, J. Ordovas-Montanes, D. Pe’re, J. Powell, S. Quake, J. Rajagopany, P.R. Tata, L.A. Rowlins, A. Regev-Apstein, M. Rojas, O. Rosen, K. Saba, P. Conforti, C. Samakovlis, H. Schiller, J.L. Schulze, M.A. Sehgal, A.E. Shalek, D. Shepherd, J. Spence, A. Spira, X. Sun, S. Teichmann, F. Theis, A. Tsankov, M. van den Berge, M. van Papen, J. Whitsett, R. Xavier, Y. Xu, L.-E. Zaragosi, K. Zhang, SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues, Cell 181 (5) (2020) 1016–1035.e19.

[6] O.O. Onabajo, A.R. Banday, M.L. Stanifer, W. Yan, A. Obajuru, D.M. Santer, O. Flores-Vargas, J.M. Vargas, T.J. Ring, G. Kee, P. Doldan, D. L. Tyrell, J.L. Mendosa, S. Boulant, L. Prekunina-Obsson, Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor, Nat Genet 52 (13) (2020) 1283–1293.

[7] K.W. Ng, J. Attig, W. Bolland, et al., Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option, Nat Genet 52 (2020) 1294–1302, https://doi.org/10.1038/s41588-020-00732-8.

[8] C. Blume, C.L. Jackson, C.M. Spalluto, J. Legebeke, L. Nazlamova, F. Conforti, J.-M. Perotin, M. Frank, J. Butler, M. Crispin, J. Coles, J. Thompson, R.A. Ridley, L.S. U. Dean, M. Loxham, S. Reikunina, A. Azim, K. Tariq, D.A. Johnston, P.J. Skipp, R. Dijkmanovic, D. Baralle, E. McCormick, D.E. Davies, J.S. Lucas, G. Wheway, V. Mennella, A novel ACE2 isoform is expressed in human respiratory epithelium and is upregulated in response to interferons and RNA respiratory virus infection, Nat Genet 53 (2) (2021) 205–214.

[9] C. Scaglioni, C. Bittoni, A. Viscido, F. Frasca, G. Oliveto, M. Scordiso, L. Petrzarca, E. Mancino, R. E. R. Nenna, E. Riva, C. De Vito, F. Midulla, G. Antonelli, A. Pierangelii, ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry? Cytokine 140 (2021), https://doi.org/10.1016/j.cyto.2021.155997.

[10] G. Mpekoulis, E. Frakolaki, S. Taka, A. Ioanidinis, A.G. Vassiliou, K.I. Kalliomapaku, K. Patas, I. Karakastiotis, V. A. A. Vasiladou, S. Chatzijasianiotou, E. Angelakis, D. Vasilakopoulos, N. Vassilaki, E.F. Meurs, Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform, PLoS One. 16 (6) (2021 Jun 29), https://doi.org/10.1371/journal.pone.0253458.

[11] H.K. Lee, O. Jung, L. Hennighausen, JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells, Commun Biol 4 (2021) 654, https://doi.org/10.1038/s42003-021-02167-1.

[12] Y.-E. Zhou, M.-U. Wang, Y. Li, P. Wang, P. Zhao, Z. Yang, S. Wang, L. Zhang, Z. Li, K. Jia, C. Zhong, N. Li, Y. Yu, J. Hou, SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating interferon effects in bronchial epithelium, Immunol Lett 237 (2021) 33–41.

[13] J. Chou, P.G. Thomas, A.G. Randolph, Immunology of SARS-CoV-2 infection in children, Nat Immunol 23 (2) (2022) 177–185.

[14] I. Glowacka, S. Bertram, P. Herzog, S. Pfefferle, I. Steffen, M.O. Muench, G. Simmons, H. Hofmann, T. Kuri, F. Weber, J. Eichler, C. Drosten, S. Pöhlmann, Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63, J Virol 84 (2) (2010) 1198–1205.

[15] C.G.K. Ziegler, V.N. Miao, A.H. Owings, A.W. Navia, Y. Tang, J.D. Bromley, P. Lotfy, M. Sloan, H. Laird, H.B. Williams, M. George, R.S. Drake, T. Christian, A. Parker, C.B. Sindel, M.W. Burger, Y. Pride, M. Hasan, G.E. Abraham, M. Senitko, T.O. Robinson, A.K. Shalek, S.C. Glover, B.H. Wheway, J. Ordovas-Montanes, Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19, Cell. 184 (18) (2021) 4713–4733.e22.